Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754415 | 0.80 | SCN10A (0.43) | ARANO1 | |
| SCHEMBL21790580 | 0.72 | NAAA (0.41) | CNR1CNR2TLR8TLR7CYP3A4 | |
| SCHEMBL25861368 | 0.70 | GAA (0.40) | CNR1CNR2TLR8CYP3A4TSHR | |
| SCHEMBL1803862 | 0.69 | LNPEP (0.47) | PKMKDM4ECYP3A4MAPTALOX15 | |
| SCHEMBL18387845 | 0.68 | SMN1; SMN2 (0.47) | PKMKDM4ETP53ALOX15 | |
| SCHEMBL19684783 | 0.67 | TLR8 (0.57) | TLR8TLR7 | |
| SCHEMBL23697921 | 0.67 | TLR8 (0.44) | CNR1CNR2TLR8TLR7KDM4E | |
| SCHEMBL20652765 | 0.67 | ADORA3 (0.39) | ARSCN9AKDM4EMAPTTSHR | |
| SCHEMBL23633882 | 0.66 | GAA (0.46) | TLR8SOAT1 | |
| SCHEMBL25857253 | 0.66 | GAA (0.46) | TLR8TLR7MAPTSOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | AR 1806/4885CNR1 3295/4885CNR2 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.